Abstract Introduction Sleep-disordered breathing (SDB) is a major comorbidity in idiopathic pulmonary fibrosis (IPF) and is associated with a poor outcome.There is a lack of knowledge regarding the impact of SDB treatment on IPF.We assessed at one year: (1) the effect of CPAP and/or nocturnal oxygen therapy on IPF regarding lung function, blood mediators, and quality of life; (2) adherence to SDB treatment and SDB changes.Methodology This is a prospective study of consecutive newly diagnosed IPF patients initiating anti-fibrotic treatment.
Lung function, polysomnography, blood tests and quality of life questionnaires were performed at inclusion and after one year.Patients were classified as FRANKINCENSE OIL 20% obstructive sleep apnoea (OSA), central sleep apnoea (CSA), and sleep-sustained hypoxemia (SSH).SDB therapy (CPAP and/or nocturnal oxygen therapy) was initiated if needed.Results Fifty patients were enrolled (36% had OSA, 22% CSA, and 12% SSH).
CPAP was started in 54% of patients and nocturnal oxygen therapy in 16%.At one-year, polysomnography found improved parameters, though 17% of patients had to add nocturnal oxygen therapy or CPAP, while 33% presented SDB onset at this second polysomnography.CPAP compliance at one year was 6.74 h/night (SD 0.
74).After one year, matrix metalloproteinase-1 decreased in OSA and CSA (p = 0.029; p = 0.027), C-reactive protein in OSA (p = 0.
045), and surfactant protein D in CSA group (p = 0.074).There was no significant change in lung function.Conclusions Treatment of SBD with CPAP and NOT can be well tolerated with a Paykel OB60HDEX3 Double Built-Under Electric Oven high compliance.
IPF patients may exhibit SDB progression and require periodic re-assessment.Further studies to evaluate the impact of SDB treatment on lung function and serological mediators are needed.